Nipple Delay Prior to Nipple Sparing Mastectomy: A Pilot RCT
Nipple Delay Prior to Nipple Sparing Mastectomy: A Pilot RCT
The goal of nipple-sparing mastectomy (NSM) with immediate breast reconstruction is to
 reconstruct a breast mound with preservation a patient's natural skin envelope. Preservation
 of the nipple and areola complex during mastectomy and breast reconstruction is associated
 with improved quality of life and a better cosmetic result. However, this surgical technique
 relies on tenuous blood supply to maintain the nipple and areola. Therefore a certain
 proportion of women will actually lose their preserved nipple-areolar complex due to vascular
 insufficiency. Furthermore, some women may find out after a nipple-sparing mastectomy that
 cancer had invaded the nipple-areolar complex, and would require another operation to
 completely remove the cancer. Despite these devastating complications, there have been no
 controlled studies to investigate mechanisms to reduce the chance of their occurrence.

 Our research study will use a pre-operative minor procedure to enhance blood flow to the
 nipple-areola complex prior to standard nipple sparing mastectomy among eligible women
 undergoing mastectomy for breast cancer or risk reduction. A secondary objective is to test
 how many women actually have active cancer in their nipple at the time of this minor surgical
 procedure, prior to standard NSM. The investigators hypothesize that our innovative and novel
 nipple-delay procedure will reduce the risk of loss of the nipple due to vascular
 insufficiency and may be of benefit to identify the small proportion of women with
 nipple-areola complex involvement, in order to optimize the ultimate cancer ablation.

 For this study the investigators propose to undertake a Pilot RCT as the first step in the
 evaluation of a delay procedure prior to NSM, and the results will be used to determine the
 feasibility and inform the optimal design for a definitive RCT. This study question has the
 potential to set a new standard of care in the management of women seeking NSM for the
 management of their breast cancer.
The surgical management of breast cancer has evolved over the last few decades, with cancer
 extirpation becoming less aggressive in parallel with advances in breast reconstruction.
 Preservation of the nipple-areolar complex (NAC) at time of mastectomy (nipple-sparing
 mastectomy, NSM), represents a natural progression within reconstructive and surgical
 oncology to preserve maximum native skin as is oncologically feasible. NSM is associated with
 improved satisfaction, body image and psychological adjustment. NSM has received increased
 attention in the lay media, because the ability to preserve the entire breast envelope
 appeals to patients facing the decision to undergo mastectomy.

 Clinician attention regarding NSM has focused on the oncologic implications of the residual
 breast tissue. Several systematic reviews of prospective and retrospective studies (level II
 to IV) have concluded that NSM does not impair overall or breast cancer specific survival
 outcomes compared to skin-sparing mastectomy. This has fostered the adoption of NSM within
 North America and Europe. The rate of occult NAC involvement ranges from 6 - 30%.

 However, the intended purpose of NSM to preserve the NAC may be circumvented if a tenuous
 sub-dermal blood supply compromises NAC viability. Rates of NAC necrosis are variable, from
 0% to nearly 50% of cases 5,6. Few studies explored strategies to prevent this potentially
 devastating complication. Recent case series employ the use of the surgical delay phenomenon
 to improve vascular supply and reduce NAC necrosis during NSM 9,10, however this strategy has
 not been directly compared with standard NSM.

 There have been no controlled studies to investigate mechanisms to reduce the chance of
 potentially devestating complication of NAC necrosis or minimize the clinical impact of
 occult tumor involvement in the NAC. Because our study is a pilot feasibility study, we have
 3 specific rationale to support our design using a pilot study first:

 1. : Given lack of evidence to support impaired cancer outcomes, there has been greater
 interest in NSM within our breast cancer community. Prior to initiating a full trial, it
 is paramount to determine the extent to which the intervention can be provided as
 intended.

 2. There are a number of well-described challenges to undertaking a RCT of a surgical
 intervention, and the extent to which women consent to participate, maintain randomized
 treatment allocation and adhere to study protocol will inform whether this study is
 feasible at a larger scale. It has not been determined whether candidates for NSM would
 accept an additional surgical procedure to reduce the risk of NAC necrosis. Lastly,
 there is the opportunity to identify and revise organization and protocols prior to
 execution within a full trial.

 3. : Given there is wide variation in reported rates of NAC necrosis, it is important to
 determine the incidence of NAC necrosis within our institutions and use this information
 to generate and inform sample size calculation. The direction of benefit and preliminary
 estimates of the effect of the intervention will clarify the choice of primary and
 secondary outcomes and feasibility for a larger scale study.

 The overarching hypothesis driving the main trial is that patients who are allocated to
 nipple-delay will have a lower rate of NAC necrosis. Additionally we hypothesize may be of
 benefit to identify the small proportion of women with nipple-areola complex involvement, in
 order to optimize the ultimate cancer ablation.

 Aim 1: To assess treatment fidelity and acceptability to surgeons of the intervention
 Hypothesis: This pilot RCT will be acceptable to surgeons, and surgeons will adhere to the
 treatment group (surgical procedure) to which their patient is randomly allocated. Aim 2: To
 determine feasibility and acceptability to patients of randomization, treatment uptake and
 retention and data-collection Hypothesis: This pilot RCT will be feasible to implement and
 acceptable to patients, and the results will inform planning of the main study. Aim 3: To
 estimate the proportion of patients in the treatment and control groups that develop NAC
 necrosis (primary outcome) and a preliminary estimate of the effect of the intervention on
 NAC necrosis (primary outcome), occult cancer and intra-operative NAC perfusion (secondary
 outcomes). Hypothesis: This pilot study will provide important information regarding
 treatment effect estimate and variability (standard deviation) that will be used to guide the
 design and sample size calculation for the main trial. The overarching hypothesis driving the
 main trial is that patients who are allocated to nipple-delay will have a lower rate of NAC
 necrosis.

 Pilot outcomes: Treatment fidelity and acceptability to surgeons: We will record the
 proportion of participants who received their randomly allocated treatment assignment to
 monitor participant adherence to treatment allocation. We will record reasons why any
 deviation from study protocol occurred (patient or surgeon-driven), and other organizational
 barriers to meeting usual care (ex: > 21 days between nipple-delay and NSM for
 experimental-group patients). Feasibility and acceptability of randomization, treatment
 allocation and data-collection procedures: Patient recruitment and attrition rates will be
 recorded. We will measure the proportion of participants that generate complete primary and
 secondary outcome measurements and baseline questionnaires.

 Trial outcomes:

 Primary outcome: We will compare the proportion of patients in each group that develop NAC
 necrosis, defined as necrosis requiring local wound care with dressings or surgical
 debridement. The proportion of patients in each group that develop total (> 75% of NAC) and
 partial (25 to 75% of NAC) NAC necrosis will be measured at 2 week and 4 weeks after the
 definitive NSM procedure by the treating plastic surgeon and surgical oncologist,
 respectively. We will take photographs to provide objective documentation.

 Secondary outcomes:

 1. The proportion of women in each group who require secondary NAC excision due to positive
 pathology review after NSM after the retro-areolar and nipple core biopsy during
 surgical delay (intervention group) or definitive NSM (control group).

 2. To include an objective and immediate measure of NAC perfusion, we will compare the mean
 perfusion score of the NAC between groups using indocyanine green infusion and the SPY
 Imaging System (Lifecell Corp.) immediately after tissue expander or implant placement
 and skin closure during the NSM. We will use this as an objective measure of perfusion
 but will not influence clinical decision making with regards to NAC viability.

 For the pilot, this study is significant to generate high-quality evidence-based data and to
 determine the feasibility to undertake and complete a full-scale RCT. The overarching study
 has the potential to influence clinical practice and is very contemporary in the management
 of patients undergoing mastectomy for breast cancer or risk reduction. If nipple-delay is
 effective in reducing the rate of NAC necrosis, then our proposed intervention has the
 potential to change clinical practice for surgeons who treat women with breast cancer or at
 high risk for development. Furthermore, the identification of occult malignancy within the
 NAC prior to planned NSM may contribute to improved cancer outcomes by not sparing the NAC at
 the time of mastectomy. We hypothesize a positive outcome would engender support within the
 breast cancer community to uptake an additional stage. Therefore, our proposed study can be
 used as a model to incorporate level I evidence into the plastic surgery research community,
 as well as provide robust data to support a change in clinical practice to improve patient
 outcomes among women undergoing NSM for breast cancer risk-reduction.
Inclusion Criteria:

 1. Patient age 18 years and above

 2. Implant-based immediate breast reconstruction

 3. Prophylactic mastectomy for risk reduction OR

 4. Therapeutic mastectomy for ductal carcinoma in situ (DCIS) or early stage breast
 cancer where:

 a. Tumor size < 3cm b. Tumor to nipple distance > 2cm c. Clinically negative lymph nodes d.
 No skin involvement, inflammatory breast cancer or Paget's disease

 Exclusion Criteria:

 1. Previous ipsilateral breast irradiation

 2. Regnault ptosis grade II or III

 3. Breast size of D cup or greater

 4. Active smoker 7. Are there any age,